



### Materials Inspection Record

1. Licensee Name: McLaren Lapeer Region		2. Docket Number(s): 030-02102		3. License Number(s) 21-11553-01	
4. Report Number(s): 2021-001			5. Date(s) of Inspection: April 30, 2021		
6. Inspector(s): Ryan Craffey		7. Program Code(s): 02121	8. Priority: 5	9. Inspection Guidance Used: IP 87130	
10. Licensee Contact Name(s): Zachary Wallin - Imaging Services Manager		11. Licensee E-mail Address: zachary.wallin@mclaren.org		12. Licensee Telephone Number(s): 810-667-5760	
13. Inspection Type:		14. Locations Inspected:		15. Next Inspection Date (MM/DD/YYYY):	
<input type="checkbox"/> Initial <input checked="" type="checkbox"/> Routine <input checked="" type="checkbox"/> Announced <input type="checkbox"/> Non-Routine <input type="checkbox"/> Unannounced		<input checked="" type="checkbox"/> Main Office <input type="checkbox"/> Field Office <input type="checkbox"/> Temporary Job Site <input checked="" type="checkbox"/> Remote		04/30/2026 <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Extended <input type="checkbox"/> Reduced <input type="checkbox"/> No change	

**16. Scope and Observations:**

This was a routine inspection of a 222-bed community hospital in Lapeer, Michigan, authorized to use byproduct material for diagnostic medical purposes. At the time of the inspection, two full-time technologists performed 2-6 diagnostic administrations of radiopharmaceuticals daily, using unit doses. The licensee retained the services of a medical physics consultant to perform quarterly audits, and held quarterly radiation safety meetings which the RSO, consultant, and imaging services manager attended. In accordance with current agency policy during the Covid-19 PHE, this inspection was announced and conducted remotely by means of video teleconferencing. Relevant records were reviewed via email.

Using the video teleconference platform, the licensee's staff provided tours of the nuclear medicine department at the hospital in Lapeer. All areas were properly posted, and all licensed material was adequately secured. The inspector observed the receipt of packages containing licensed material, as well as demonstrations of the preparation of diagnostic radiopharmaceuticals, instrument quality control checks, area surveys, and waste handling. At the inspector's request, the licensee performed additional surveys in restricted and unrestricted areas. No evidence of residual contamination or exposures in excess of regulatory limits were noted. Moreover, radiation instrumentation was calibrated and operable, and staff were knowledgeable of radiation protection principles, licensee procedures and regulatory requirements, and utilized appropriate dosimetry and ALARA practices throughout. The inspector also discussed the status and oversight of the program with licensee management.

Prior to these observations and interviews, the inspector reviewed a selection of licensee records via email. These included personnel dosimetry reports, quarterly consultant audits, package receipt documentation, area survey results, and decay-in-storage waste disposal documentation.

No violations of NRC requirements were identified as a result of this inspection.